

CVS CAREMARK

CVS

Caremark (NYSE: CVS) was upgraded by equities research analysts at RBC Capital (NYSE: RY) from a "sector perform" rating to an "outperform" rating in a research note issued to investors on Monday. The analysts currently have a \$44.00 price target on the stock, up from their previous price target of \$36.00.

Separately, analysts at Morgan Stanley (NYSE: MS) upgraded shares of CVS Caremark from an "equal weight" rating to an "overweight" rating in a research note to investors on Friday. They now have a \$44.00 price target on the stock. Analysts at Citigroup (NYSE: C) raised their EPS on shares of CVS Caremark in a research note to investors on Monday, October 24th. They now have a "buy" rating and a \$45.00 price target on the stock. Also, analysts at Goldman Sachs (NYSE: GS) cut their EPS estimates on shares of CVS Caremark in a research note on Monday. They now have a "neutral" rating and a \$24.00 price target on the stock.

CVS Caremark Corporation (CVS Caremark) is a health care provider in the United States. It is a pharmacy services company and provides value for its customers by managing pharmaceutical costs and improving health care outcomes through its pharmacy benefit management, mail order and specialty pharmacy division, Caremark Pharmacy Services; approximately 7,000 CVS/pharmacy retail stores; retail-based health clinic subsidiary, MinuteClinic, and through its online pharmacy, CVS.com. The Company operates in two business segments: Pharmacy Services segment and Retail Pharmacy segment.

Shares of CVS Caremark opened at 38.06 on Monday. CVS Caremark has a 52 week low of \$29.45 and a 52 week high of \$39.50. The stock's 50-day moving average is \$34.94 and its 200-day moving average is